scholarly journals Local application of non-steroidal anti-inflammatory drugs: advantages and disadvantages

2021 ◽  
Vol 17 (6) ◽  
pp. 37-42
Author(s):  
A.V. Makogonchuk ◽  
Yu.O. Bezsmertnyi ◽  
L.Ye. Atamanchuk

The article presents literature data on the efficacy and safety of dexketoprofen trometamol gel when applied locally and comparative characteristics of this pharmacological agent with other transdermal forms of nonsteroidal anti-inflammatory drugs. It was found that dexketoprofen when applied topically in the form of a gel has a high ability to accumulate in the skin, muscle and nervous (neurons, myelin and hypothalamus) tissues which causes a good anti-inflammatory, anti-edema and analgesic effect of this drug. Dexketoprofen showed a low level of accumulation in the cartilage without stimulating degenerative changes in cartilage tissue, as it does not inhibit the synthesis of proteoglycans by chondrocytes. At the same time, dexketoprofen had a low capacity for accumulation in blood cells and in internal organs demonstrating a low pro-bability of systemic side effects.

2021 ◽  
Vol 5 (2) ◽  
pp. 96-101
Author(s):  
V.B. Vasilyuk ◽  
◽  
G.I. Syraeva ◽  
M.V. Faraponova ◽  
◽  
...  

Gout is one of the most common forms of inflammatory arthritis. Medical care for gout includes non-steroidal anti-inflammatory drugs (NSAIDs). This paper reviews the efficacy and safety of NSAIDs prescribed for the acute attack of gout, in particular, AMBENIUM® parenteral. It was demonstrated that phenylbutazone is a powerful NSAID that provides significant analgesic and anti-inflammatory effects. Considering a broad spectrum of adverse reactions of NSAIDs, these agents should be prescribed and used under in-depth analysis of patient’s condition, comorbidities and the level of their decompensation, and potential drug interactions. In addition, optimal dosages and duration of NSAID treatment are of particular importance. The authors conclude that AMBENIUM® parenteral is an effective and safe therapeutic modality for gout. Its profile and risk/benefit ratio are regarded as “favorable” compared to other NSAIDs. KEYWORDS: gout, arthritis, pain, non-steroidal anti-inflammatory drugs, parenteral, efficacy, safety. FOR CITATION: Vasilyuk V.B., Syraeva G.I., Faraponova M.V. Efficacy and safety of non-steroidal anti-inflammatory drugs for acute attack of gout. Russian Medical Inquiry. 2021;5(2):96–101. DOI: 10.32364/2587-6821-2021-5-2-96-101.


2020 ◽  
Vol 12 (2) ◽  
pp. 42-47
Author(s):  
E. Yu. Plotnikova ◽  
V. N. Zolotukhina ◽  
L. K. Isakov ◽  
M. N. Sinkova ◽  
M. A. Sinkov

1980 ◽  
Vol 18 (3) ◽  
pp. 9-11

In 1975 the Committee on the Review of Medicines (CRM) began to examine the efficacy and safety of those drugs that were already on the market before 1971, when the present licensing procedures were introduced.1 It has already made recommendations on non-steroidal anti-inflammatory drugs2 and on other drugs used in rheumatic diseases,3 and these led to improvements in the data sheets for these products but had no obvious effects in practice. However, with its most recent recommendations on barbiturates, the CRM is showing its teeth.


Sign in / Sign up

Export Citation Format

Share Document